A Phase 2 interventional study of LGX818 and MEK162 in Melanoma, sponsored by Pfizer. Completed at 32 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing encorafenib in Melanoma — 4 open to participants now, 8 under way, 2 of them phase 3. encorafenib · Melanoma.
Among the 27 studies testing encorafenib in Melanoma, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 14 in phase 2, and was the 6th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →4 of the 27 studies testing encorafenib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
SWOG Cancer Research Network · Sites in United States
Ages 18+
Peter MacCallum Cancer Centre, Australia · Sites in Australia
Ages 18–100
Inge Marie Svane · Sites in Denmark
Ages 18+
By country, each count listing its studies:
encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 18 · Phase 3 3 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 35 across the 27 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 27 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
52 studies in Melanoma by Pfizer: 1 open now, 4 under way, 1 of them phase 3. Of 47 finished, 23 (49%) have results posted.
Among the 52 studies in Melanoma by Pfizer, this one is the 13th largest by enrollment of the 48 interventional ones that give a count, is the only one that started in 2014, is one of 13 in phase 2, and was the 19th registered.
Pfizer’s Melanoma studies by the year they started, since 2002.
3 of the studies testing encorafenib in Melanoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT05026983M.D. Anderson Cancer CenterBinimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | 2027-02-02 |
| NCT04511013SWOG Cancer Research NetworkA Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies testing encorafenib in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 52 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.
This study consists of two parts: in Part I/Run-In, patients naïve to selective BRAF and MEK inhibitors will be treated with the LGX818/MEK162 combination until disease progression (as defined per RECIST v1.1). Based on the genetic analysis of a tumor biopsy obtained at that time, patients will enter Part II of the study for tailored combination treatment in one of four arms of LGX818/MEK162 + either BKM120, BGJ398, INC280 or LEE011 Patients with BRAF mutant melanoma treated by LGX818/MEK162 combination in other studies can be enrolled directly in Part II of CLGX818X2109 after relapse.
Dose-escalations in the combination arms for which no MTD has been established will be based on the recommendations of a Bayesian logistic regression model guided by an escalation with overdose control criterion
INCLUSION CRITERIA:
INCLUSION CRITERIA for triple combinations:
Progressive disease following prior treatment with LGX818/MEK162 combination. PRINCIPAL EXCLUSION CRITERIA Symptomatic or untreated .
Screening/baseline:
Additional exclusion criteria for the triple combinations:
LGX818/MEK162/BKM120:
Investigator or a Psychiatrist:
LGX818/MEK162/BGJ398:
LGX818/MEK162/LEE011:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LGX818 · Drug: MEK162
Drug: LEE011
Drug: BGJ398
Drug: BKM120
Drug: INC280
Combination of LGX818 and MEK162 (Part I)
Combination of LGX818 and MEK162 (Part I)
Combination of LGX818 + MEK162 + LEE011 (Part II)
Combination of LGX818 + MEK162 + BGJ398 (Part II)
Combination of LGX818 + MEK162 + BKM120 (Part II)
Combination of LGX818 + MEK162 + INC280 (Part II)
Overall Response Rate (ORR): Part II
ORR: percentage of participants with confirmed complete response (CR) and partial response (PR). Response evaluation criteria in solid tumors (RECIST) v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions that had a reduction in short axis to less than (\<) 10 millimeter (mm). Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30 percent (%) decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Any radiological assessments taken more than 30 days after the last dose of study therapy or after antineoplastic agents other than study treatments taken by the participants was excluded from the best overall response derivation. Confirmation of CR or PR was to be at least 4 weeks apart from the previous radiological assessment.
Time frame: From the start of the treatment until disease/clinical progression or death or early study discontinuation, whichever happened earlier (maximum treatment exposure for Part II was 97.0 weeks)
Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II
DLT was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle (first 21 days for infigratinib and capmatinib; 28 days for ribociclib and buparlisib) of treatment initiation and met the defined criteria for study.
Time frame: Cycle 1 (21 days following the first dose of the combination treatment with buparlisib and capmatinib; 28 days for the combination with ribociclib and infigratinib)
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I
An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.
Time frame: Day 1 up to 30 days after last dose (maximum treatment exposure for Part I was 403.7 weeks)
Number of Participants With AEs and SAEs: Part II
An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.
Time frame: Day 1 up to 30 days after last dose (maximum treatment exposure for Part II was 97.0 weeks)
Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I
Parameters evaluated were: Activated partial thromboplastin time (APTT) (seconds \[sec\]) - CTCAE graded high, fibrinogen (gram per liter \[g/L\]) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, prothrombin international normalized ratio (PINR) - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment.
Time frame: Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)
Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II
Parameters evaluated were: APTT (sec) - CTCAE graded high, fibrinogen (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, PINR - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment in Part II.
Time frame: Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)
Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I
Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (units per liter \[U/L\])- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (micromole per liter \[umol/L\])- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (millimole per liter \[mmol/L\])- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.
Time frame: Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)
Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II
Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (U/L)- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L) - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (umol/L)- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (mmol/L)- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.
Time frame: Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)
Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I
Vital signs evaluated were: Low/high systolic blood pressure (BP) (millimeter of Mercury \[mmHg\]): less than or equal to (\<=) 90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (beats per minute \[bpm\]): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kilogram \[kg\]): \>=20% decrease/increase from baseline; and low/high body temperature (degree Celsius \[C\]): \<=36 C / \>= 37.5 C.
Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II
Vital signs evaluated were: Low/high systolic BP (mmHg): \<=90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (bpm): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kg): \>=20% decrease/increase from baseline; and low/high body temperature (C): \<=36 C / \>= 37.5 C.
Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Number of Participants With Notable Electrocardiograms (ECG) Values: Part I
Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: Heart rate (HR): increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 millisecond (ms); QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and Corrected QT interval by Fridericia (QTcF): increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.
Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Number of Participants With Notable ECG Values: Part II
Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: HR: increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 ms; QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and QTcF: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.
Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Number of Participants With At Least One Dose Interruption: Part I
In this outcome measure number of participants with at least 1 dose interruption for encorafenib and binimetinib were reported.
Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Number of Participants With At Least One Dose Interruption: Part II
In this outcome measure number of participants with at least 1 dose interruption for encorafenib, binimetinib, and each third combination agent were reported.
Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Number of Participants With At Least One Dose Reduction: Part I
In this outcome measure number of participants with at least 1 dose reduction for encorafenib and binimetinib were reported.
Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Number of Participants With At Least One Dose Reduction: Part II
In this outcome measure number of participants with at least 1 dose reduction for encorafenib, binimetinib, and each third combination agent were reported.
Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Actual Dose Intensity: Part I
Dose intensity across all cycles = cumulative dose/duration of exposure. Treatment cycle for encorafenib and binimetinib =21 days.
Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Actual Dose Intensity: Part II
Dose intensity = cumulative dose/ duration of exposure. Treatment cycle = 21days for the combination treatment with buparlisib and capmatinib and 28 days for the combination treatment with ribociclib and infigratinib.
Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Progression-Free Survival (PFS): Part I
PFS was defined as the time from the start date of study drug in Part I until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.
Time frame: From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part I was 403.7 weeks)
PFS: Part II
PFS was defined as the time from the start date of study drug in Part II until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.
Time frame: From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)
Duration of Response (DOR): Part I
DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From date of first documented response (CR or PR) till the date of first documented progression or death due to underlying cancer or censoring date (maximum treatment exposure for Part I was 403.7 weeks)
DOR: Part II
DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From date of first documented response (CR or PR) till the date of first documented progression or death due to underlying cancer or censoring date (maximum treatment exposure for Part II was 97.0 weeks)
Time to Response (TTR): Part I
TTR was defined as the time between the start date of study drug in Part I and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.
Time frame: From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part I was 403.7 weeks)
TTR: Part II
TTR was defined as the time between the start date of study drug in Part II and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.
Time frame: From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part II was 97.0 weeks)
Disease Control Rate (DCR): Part I
DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part I was 403.7 weeks)
DCR: Part II
DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part II was 97.0 weeks)
Overall Survival (OS): Part II
OS was defined as the time from the start date of study treatment (3rd agent combined with encorafenib and binimetinib) to date of death due to any cause. If a participant was not known to have died, survival was censored at the date of last known date participant alive. Kaplan Meier method used for estimation.
Time frame: From date of start of treatment to date of death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)
Summary of Genomic Biomarkers From Tumor Samples: Part I
Number of participants with multiple alterations in genomic biomarkers like biomarker BRAF, CCND1, CDK4, EGFR, FGFR1, FGFR4, KRAS, MET, NRAS, PIK3CA, and PTEN were reported and alterations included copy number variant/copy number ratio (CNV/CNR), rearrangement, short variant. It was not necessary that all biomarkers had all alterations. Baseline = last non-missing value prior to the first dose of study treatment.
Time frame: Baseline up to end of treatment (EOT) (maximum treatment exposure for Part I was 403.7 weeks)
Plasma Concentration for Encorafenib (LGX): Part I
In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5) and end of treatment (EOT). Maximum treatment exposure for Part I was of 403.7 weeks.
Time frame: C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT
Plasma Concentration for Encorafenib (LGX): Part II
In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 16 (D16), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5). Maximum treatment exposure for Part II was of 97.0 weeks.
Time frame: C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I
AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part I was of 403.7 weeks.
Time frame: C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT
Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II
AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part II was of 97.0 weeks.
Time frame: C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II
LEQ803 is metabolite of ribociclib. Maximum treatment exposure for Part II was of 97.0 weeks.
Time frame: C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II
BHS697 and CQM157 are metabolites of infigratinib. Maximum treatment exposure for Part II was of 97.0 weeks.
Time frame: C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; EOT
Plasma Concentration for Capmatinib (INC): Part II
Maximum treatment exposure for Part II was of 97.0 weeks.
Time frame: C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Plasma Concentration for Buparlisib (BKM): Part II
Maximum treatment exposure for Part II was of 97.0 weeks.
Time frame: C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Time frame: C1 D15: 0.5 hour ± 10 (minutes) min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II
Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II
Elimination half-life means the time required for the plasma concentration to decline by 50% during the elimination phase.
Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution is the apparent volume of distribution at steady-state.
Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Time frame: C1 D15: at the end of a dosing interval at steady-state (24 hour ± 2 hour), taken directly before next administration
This study had 2 parts. In Part I, 158 participants were enrolled and treated with encorafenib/ binimetinib (LGX818/MEK162) combination until disease progression (PD) \[as per RECISTv1.1\]. Based on the genetic assessment of a tumor biopsy obtained at PD, participants from Part I entered Part II. In Part II, 58 participants received tailored combination treatment in one of the 4 arms: encorafenib/ binimetinib + buparlisib (BKM120), infigratinib (BGJ398), capmatinib (INC280) or ribociclib (LEE011).
| Milestone | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|---|---|
| Started | 75 | 83 | 0 | 0 | 0 | 0 |
| Completed | 0 | 4 | 0 | 0 | 0 | 0 |
| Not completed | 75 | 79 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 7 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 11 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 37 | 46 | 0 | 0 | 0 | 0 |
| Withdrew: New therapy for study indication | 5 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Termination of participants from the study | 3 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Participant/guardian decision | 9 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Missing data | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 38 | 1 | 13 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 38 | 1 | 13 | 6 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 2 | 1 |
| Withdrew: Progressive disease | 0 | 0 | 35 | 1 | 7 | 4 |
| Withdrew: New therapy for study indication | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant/guardian decision | 0 | 0 | 0 | 0 | 2 | 0 |
ORR: percentage of participants with confirmed complete response (CR) and partial response (PR). Response evaluation criteria in solid tumors (RECIST) v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions that had a reduction in short axis to less than (\<) 10 millimeter (mm). Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30 percent (%) decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Any radiological assessments taken more than 30 days after the last dose of study therapy or after antineoplastic agents other than study treatments taken by the participants was excluded from the best overall response derivation. Confirmation of CR or PR was to be at least 4 weeks apart from the previous radiological assessment.
| Percentage of participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| Overall Response Rate (ORR): Part II | 2.6 (0.1 to 13.8) | 0 (NA to NA) | 0 (0.0 to 24.7) | 0 (0.0 to 45.9) |
DLT was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle (first 21 days for infigratinib and capmatinib; 28 days for ribociclib and buparlisib) of treatment initiation and met the defined criteria for study.
| Participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II | 1 | — | 0 | — |
An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.
| Participants | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| AEs | 75 | 78 |
| SAEs | 47 | 37 |
An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.
| Participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| AEs | 37 | 1 | 12 | 6 |
| SAEs | 19 | 0 | 6 | 4 |
Parameters evaluated were: Activated partial thromboplastin time (APTT) (seconds \[sec\]) - CTCAE graded high, fibrinogen (gram per liter \[g/L\]) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, prothrombin international normalized ratio (PINR) - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment.
| Participants | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| APTT -CTCAE graded high — Worst post-baseline value Grade 0 | 46 | 54 |
| APTT -CTCAE graded high — Worst post-baseline value Grade 1 | 1 | 4 |
| APTT -CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 |
| APTT -CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 |
| APTT -CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| APTT -CTCAE graded high — Worst post-baseline value Missing | 28 | 25 |
| Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 0 | 28 | 36 |
| Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 1 | 8 | 9 |
| Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 2 | 5 | 7 |
| Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 3 | 4 | 1 |
| Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Fibrinogen - CTCAE graded low — Worst post-baseline value Missing | 30 | 30 |
| Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 0 | 21 | 17 |
| Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 1 | 28 | 39 |
| Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 2 | 18 | 20 |
| Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 3 | 8 | 6 |
| Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Hemoglobin - CTCAE graded low — Worst post-baseline value Missing | 0 | 1 |
| Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 0 | 70 | 80 |
| Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 1 | 4 | 2 |
| Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 |
| Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 3 | 1 | 0 |
| Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Hemoglobin - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| PINR -CTCAE graded high — Worst post-baseline value Grade 0 | 44 | 34 |
| PINR -CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 2 |
| PINR -CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 |
| PINR -CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 |
| PINR -CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| PINR -CTCAE graded high — Worst post-baseline value Missing | 31 | 47 |
| Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 0 | 23 | 27 |
| Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 1 | 22 | 24 |
| Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 2 | 13 | 12 |
| Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 3 | 6 | 10 |
| Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 1 |
| Lymphocytes - CTCAE graded low — Worst post-baseline value Missing | 11 | 9 |
| Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 0 | 61 | 68 |
| Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 |
| Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 2 | 2 | 6 |
| Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 3 | 1 | 0 |
| Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Lymphocytes - CTCAE graded high — Worst post-baseline value Missing | 11 | 9 |
| Neutrophils - CTCAE graded low — Worst post-baseline value Grade 0 | 52 | 62 |
| Neutrophils - CTCAE graded low — Worst post-baseline value Grade 1 | 4 | 6 |
| Neutrophils - CTCAE graded low — Worst post-baseline value Grade 2 | 5 | 4 |
| Neutrophils - CTCAE graded low — Worst post-baseline value Grade 3 | 3 | 1 |
| Neutrophils - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Neutrophils - CTCAE graded low — Worst post-baseline value Missing | 11 | 10 |
| Platelets - CTCAE graded low — Worst post-baseline value Grade 0 | 59 | 71 |
| Platelets - CTCAE graded low — Worst post-baseline value Grade 1 | 14 | 11 |
| Platelets - CTCAE graded low — Worst post-baseline value Grade 2 | 2 | 0 |
| Platelets - CTCAE graded low — Worst post-baseline value Grade 3 | 0 | 0 |
| Platelets - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Platelets - CTCAE graded low — Worst post-baseline value Missing | 0 | 1 |
| Leukocytes - CTCAE graded low — Worst post-baseline value Grade 0 | 52 | 61 |
| Leukocytes - CTCAE graded low — Worst post-baseline value Grade 1 | 11 | 14 |
| Leukocytes - CTCAE graded low — Worst post-baseline value Grade 2 | 3 | 3 |
| Leukocytes - CTCAE graded low — Worst post-baseline value Grade 3 | 0 | 0 |
| Leukocytes - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Leukocytes - CTCAE graded low — Worst post-baseline value Missing | 9 | 5 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 0 | 66 | 78 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Missing | 9 | 5 |
Parameters evaluated were: APTT (sec) - CTCAE graded high, fibrinogen (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, PINR - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment in Part II.
| Participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| APTT- CTCAE graded high — Worst post-baseline value Grade 0 | 27 | 1 | 9 | 4 |
| APTT- CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 | 0 | 0 |
| APTT- CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| APTT- CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| APTT- CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| APTT- CTCAE graded high — Worst post-baseline value Missing | 11 | 0 | 4 | 2 |
| Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 0 | 13 | 0 | 6 | 3 |
| Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 1 | 3 | 1 | 1 | 0 |
| Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 2 | 2 | 0 | 1 | 0 |
| Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 3 | 1 | 0 | 0 | 0 |
| Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Fibrinogen: CTCAE graded low — Worst post-baseline value Missing | 19 | 0 | 5 | 3 |
| Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 0 | 4 | 0 | 4 | 2 |
| Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 1 | 15 | 1 | 5 | 1 |
| Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 2 | 14 | 0 | 2 | 1 |
| Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 3 | 4 | 0 | 1 | 2 |
| Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Hemoglobin- CTCAE graded low — Worst post-baseline value Missing | 1 | 0 | 1 | 0 |
| Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 0 | 37 | 1 | 11 | 6 |
| Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 | 1 | 0 |
| Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Hemoglobin- CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 0 |
| PINR- CTCAE graded high — Worst post-baseline value Grade 0 | 14 | 1 | 8 | 1 |
| PINR- CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 | 0 | 0 |
| PINR- CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| PINR- CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| PINR- CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| PINR- CTCAE graded high — Worst post-baseline value Missing | 24 | 0 | 5 | 5 |
| Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 0 | 5 | 0 | 4 | 2 |
| Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 1 | 7 | 0 | 4 | 3 |
| Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 2 | 9 | 0 | 3 | 1 |
| Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 3 | 7 | 0 | 0 | 0 |
| Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 4 | 1 | 0 | 0 | 0 |
| Lymphocytes -CTCAE graded low — Worst post-baseline value Missing | 9 | 1 | 2 | 0 |
| Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 0 | 29 | 0 | 11 | 6 |
| Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 | 0 | 0 |
| Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Lymphocytes- CTCAE graded high — Worst post-baseline value Missing | 9 | 1 | 2 | 0 |
| Neutrophils- CTCAE graded low — Worst post-baseline value Grade 0 | 10 | 0 | 11 | 6 |
| Neutrophils- CTCAE graded low — Worst post-baseline value Grade 1 | 9 | 0 | 0 | 0 |
| Neutrophils- CTCAE graded low — Worst post-baseline value Grade 2 | 6 | 0 | 0 | 0 |
| Neutrophils- CTCAE graded low — Worst post-baseline value Grade 3 | 1 | 0 | 0 | 0 |
| Neutrophils- CTCAE graded low — Worst post-baseline value Grade 4 | 1 | 0 | 0 | 0 |
| Neutrophils- CTCAE graded low — Worst post-baseline value Missing | 11 | 1 | 2 | 0 |
| Platelets- CTCAE graded low — Worst post-baseline value Grade 0 | 33 | 1 | 11 | 6 |
| Platelets- CTCAE graded low — Worst post-baseline value Grade 1 | 4 | 0 | 1 | 0 |
| Platelets- CTCAE graded low — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Platelets- CTCAE graded low — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Platelets- CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Platelets- CTCAE graded low — Worst post-baseline value Missing | 1 | 0 | 1 | 0 |
| Leukocytes- CTCAE graded low — Worst post-baseline value Grade 0 | 8 | 0 | 11 | 6 |
| Leukocytes- CTCAE graded low — Worst post-baseline value Grade 1 | 8 | 0 | 0 | 0 |
| Leukocytes- CTCAE graded low — Worst post-baseline value Grade 2 | 12 | 0 | 0 | 0 |
| Leukocytes- CTCAE graded low — Worst post-baseline value Grade 3 | 3 | 0 | 0 | 0 |
| Leukocytes- CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Leukocytes- CTCAE graded low — Worst post-baseline value Missing | 7 | 1 | 2 | 0 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 0 | 31 | 0 | 11 | 6 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 | 0 | 0 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Leukocytes - CTCAE graded high — Worst post-baseline value Missing | 7 | 1 | 2 | 0 |
Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (units per liter \[U/L\])- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (micromole per liter \[umol/L\])- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (millimole per liter \[mmol/L\])- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.
| Participants | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Albumin - CTCAE graded low — Worst post-baseline value Grade 0 | 32 | 40 |
| Albumin - CTCAE graded low — Worst post-baseline value Grade 1 | 35 | 29 |
| Albumin - CTCAE graded low — Worst post-baseline value Grade 2 | 8 | 12 |
| Albumin - CTCAE graded low — Worst post-baseline value Grade 3 | 0 | 1 |
| Albumin - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Albumin - CTCAE graded low — Worst post-baseline value Missing | 0 | 1 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 0 | 39 | 43 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 1 | 28 | 31 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 2 | 5 | 5 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 3 | 3 | 3 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 0 | 38 | 51 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 1 | 27 | 28 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 2 | 5 | 2 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 3 | 5 | 0 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Missing | 0 | 2 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 0 | 53 | 52 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 1 | 14 | 6 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 2 | 5 | 2 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 3 | 2 | 2 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 1 |
| Amylase - CTCAE graded high — Worst post-baseline value Missing | 1 | 20 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 0 | 38 | 50 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 1 | 30 | 29 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 2 | 4 | 2 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 3 | 3 | 1 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 0 | 73 | 81 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 1 | 1 | 0 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 2 | 1 | 0 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 1 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 0 | 22 | 56 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 1 | 30 | 15 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 2 | 18 | 8 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 3 | 4 | 2 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 4 | 1 | 1 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 0 | 2 | 4 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 1 | 57 | 56 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 2 | 14 | 22 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 3 | 2 | 0 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Creatinine - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 0 | 20 | 33 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 1 | 19 | 18 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 2 | 14 | 13 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 3 | 20 | 15 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 4 | 2 | 3 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 0 | 55 | 67 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 1 | 15 | 7 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 2 | 1 | 1 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 3 | 0 | 0 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Glucose - CTCAE graded low — Worst post-baseline value Missing | 4 | 8 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 0 | 56 | 60 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 1 | 4 | 10 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 2 | 3 | 0 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 3 | 7 | 5 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 4 | 1 | 0 |
| Glucose - CTCAE graded high — Worst post-baseline value Missing | 4 | 8 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 0 | 65 | 74 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 1 | 7 | 5 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 2 | 0 | 0 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 3 | 3 | 3 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Potassium - CTCAE graded low — Worst post-baseline value Missing | 0 | 1 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 0 | 54 | 66 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 1 | 18 | 15 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 2 | 2 | 0 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 3 | 1 | 0 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 1 |
| Potassium - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 0 | 66 | 68 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 1 | 8 | 14 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 2 | 0 | 0 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 3 | 1 | 0 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Magnesium - CTCAE graded low — Worst post-baseline value Missing | 0 | 1 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 0 | 74 | 79 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 1 | 1 | 3 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Magnesium - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 0 | 40 | 62 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 1 | 3 | 3 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 2 | 24 | 12 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 3 | 8 | 4 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 1 |
| Phosphate - CTCAE graded low — Worst post-baseline value Missing | 0 | 1 |
| Sodium - CTCAE graded low — Worst post-baseline value Grade 0 | 54 | 53 |
| Sodium - CTCAE graded low — Worst post-baseline value Grade 1 | 21 | 24 |
| Sodium - CTCAE graded low — Worst post-baseline value Grade 2 | 0 | 0 |
| Sodium - CTCAE graded low — Worst post-baseline value Grade 3 | 0 | 5 |
| Sodium - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 |
| Sodium - CTCAE graded low — Worst post-baseline value Missing | 0 | 1 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 0 | 66 | 75 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 1 | 9 | 6 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 1 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Sodium - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 0 | 75 | 82 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 |
| Urate - CTCAE graded high — Worst post-baseline value Missing | 0 | 1 |
Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (U/L)- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L) - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (umol/L)- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (mmol/L)- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.
| Participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| Albumin- CTCAE graded low — Worst post-baseline value Grade 0 | 16 | 1 | 1 | 3 |
| Albumin- CTCAE graded low — Worst post-baseline value Grade 1 | 13 | 0 | 6 | 0 |
| Albumin- CTCAE graded low — Worst post-baseline value Grade 2 | 7 | 0 | 3 | 1 |
| Albumin- CTCAE graded low — Worst post-baseline value Grade 3 | 1 | 0 | 2 | 1 |
| Albumin- CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Albumin- CTCAE graded low — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 0 | 22 | 1 | 7 | 1 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 1 | 10 | 0 | 3 | 4 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 2 | 3 | 0 | 2 | 1 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 3 | 2 | 0 | 0 | 0 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 0 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 0 | 27 | 1 | 9 | 4 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 1 | 6 | 0 | 2 | 1 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 2 | 2 | 0 | 0 | 0 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 3 | 1 | 0 | 1 | 0 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 4 | 1 | 0 | 0 | 1 |
| Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 0 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 0 | 27 | 1 | 9 | 1 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 1 | 1 | 0 | 2 | 0 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 1 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Amylase - CTCAE graded high — Worst post-baseline value Grade 4 | 2 | 0 | 0 | 0 |
| Amylase - CTCAE graded high — Worst post-baseline value Missing | 8 | 0 | 2 | 4 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 0 | 27 | 1 | 8 | 3 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 1 | 6 | 0 | 4 | 2 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 2 | 3 | 0 | 0 | 0 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 3 | 1 | 0 | 0 | 1 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 0 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 0 | 37 | 1 | 12 | 6 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 | 0 | 0 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Bilirubin - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 0 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 0 | 20 | 0 | 6 | 3 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 1 | 14 | 1 | 4 | 2 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 2 | 3 | 0 | 0 | 0 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 2 | 0 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Creatine Kinase - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 0 | 1 | 0 | 0 | 1 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 1 | 25 | 1 | 4 | 3 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 2 | 11 | 0 | 8 | 1 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Creatinine - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Creatinine - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 0 | 20 | 1 | 5 | 0 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 1 | 9 | 0 | 2 | 1 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 2 | 1 | 0 | 2 | 2 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 3 | 7 | 0 | 3 | 3 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 0 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 0 | 24 | 0 | 11 | 5 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 1 | 6 | 1 | 1 | 0 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Glucose - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Glucose - CTCAE graded low — Worst post-baseline value Missing | 8 | 0 | 1 | 1 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 0 | 26 | 1 | 10 | 4 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 1 | 2 | 0 | 1 | 1 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 3 | 1 | 0 | 1 | 0 |
| Glucose - CTCAE graded high — Worst post-baseline value Grade 4 | 1 | 0 | 0 | 0 |
| Glucose - CTCAE graded high — Worst post-baseline value Missing | 8 | 0 | 1 | 1 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 0 | 34 | 1 | 11 | 5 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 1 | 3 | 0 | 1 | 0 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Potassium - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Potassium - CTCAE graded low — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 0 | 32 | 1 | 9 | 3 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 1 | 4 | 0 | 3 | 2 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 2 | 1 | 0 | 0 | 0 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Potassium - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Potassium - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 0 | 35 | 1 | 10 | 4 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 1 | 2 | 0 | 2 | 1 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Magnesium - CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Magnesium - CTCAE graded low — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 0 | 36 | 1 | 12 | 5 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 1 | 1 | 0 | 0 | 0 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Magnesium - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Magnesium - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 0 | 25 | 1 | 7 | 4 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 1 | 2 | 0 | 1 | 1 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 2 | 7 | 0 | 3 | 0 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 3 | 1 | 0 | 1 | 0 |
| Phosphate - CTCAE graded low — Worst post-baseline value Grade 4 | 2 | 0 | 0 | 0 |
| Phosphate - CTCAE graded low — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Sodium -CTCAE graded low — Worst post-baseline value Grade 0 | 28 | 1 | 10 | 3 |
| Sodium -CTCAE graded low — Worst post-baseline value Grade 1 | 7 | 0 | 2 | 2 |
| Sodium -CTCAE graded low — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Sodium -CTCAE graded low — Worst post-baseline value Grade 3 | 2 | 0 | 0 | 0 |
| Sodium -CTCAE graded low — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Sodium -CTCAE graded low — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 0 | 35 | 1 | 12 | 4 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 1 | 2 | 0 | 0 | 1 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Sodium - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Sodium - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 0 | 37 | 1 | 12 | 5 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 1 | 0 | 0 | 0 | 0 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 2 | 0 | 0 | 0 | 0 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 3 | 0 | 0 | 0 | 0 |
| Urate - CTCAE graded high — Worst post-baseline value Grade 4 | 0 | 0 | 0 | 0 |
| Urate - CTCAE graded high — Worst post-baseline value Missing | 1 | 0 | 1 | 1 |
Vital signs evaluated were: Low/high systolic blood pressure (BP) (millimeter of Mercury \[mmHg\]): less than or equal to (\<=) 90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (beats per minute \[bpm\]): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kilogram \[kg\]): \>=20% decrease/increase from baseline; and low/high body temperature (degree Celsius \[C\]): \<=36 C / \>= 37.5 C.
| Participants | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Sitting Pulse Rate: High | 2 | 8 |
| Sitting Pulse Rate: Low | 5 | 4 |
| Sitting Systolic BP: High | 18 | 5 |
| Sitting Systolic BP: Low | 3 | 2 |
| Sitting Diastolic BP: High | 11 | 4 |
| Sitting Diastolic BP: Low | 5 | 3 |
| Weight: High | 0 | 2 |
| Weight: Low | 0 | 0 |
| Body temperature: High | 14 | 14 |
| Body temperature: Low | 44 | 36 |
Vital signs evaluated were: Low/high systolic BP (mmHg): \<=90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (bpm): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kg): \>=20% decrease/increase from baseline; and low/high body temperature (C): \<=36 C / \>= 37.5 C.
| Participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| Sitting Pulse Rate: High | 2 | 0 | 0 | 1 |
| Sitting Pulse Rate: Low | 1 | 0 | 0 | 0 |
| Sitting Systolic BP: High | 2 | 0 | 4 | 0 |
| Sitting Systolic BP: Low | 0 | 0 | 0 | 0 |
| Sitting Diastolic BP: High | 2 | 0 | 1 | 0 |
| Sitting Diastolic BP: Low | 1 | 0 | 0 | 0 |
| Weight: High | 0 | 0 | 0 | 0 |
| Weight: Low | 1 | 0 | 0 | 0 |
| Body temperature: High | 3 | 0 | 1 | 1 |
| Body temperature: Low | 14 | 1 | 6 | 3 |
Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: Heart rate (HR): increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 millisecond (ms); QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and Corrected QT interval by Fridericia (QTcF): increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.
| Participants | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| HR: Increase from baseline >25% & to a value >100 bpm | 10 | 5 |
| HR: Decrease from baseline >25% & to a value <60 bpm | 37 | 23 |
| PR: Increase from baseline >25% & to a value >200 ms | 5 | 1 |
| QRS: Increase from baseline >25% & to a value >110 ms | 3 | 0 |
| QT: Increase from baseline >30 ms | 61 | 48 |
| QT: Increase from baseline >60 ms | 29 | 15 |
| QT: New Interval >450 ms | 24 | 4 |
| QT: New Interval >480 ms | 5 | 3 |
| QT: New Interval >500 ms | 3 | 0 |
| QTcF: Increase from baseline >30 ms | 46 | 31 |
| QTcF: Increase from baseline >60 ms | 4 | 2 |
| QTcF: New Interval >450 ms | 28 | 15 |
| QTcF: New Interval >480 ms | 4 | 0 |
| QTcF: New Interval >500 ms | 1 | 0 |
Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: HR: increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 ms; QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and QTcF: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.
| Participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| HR: Increase from baseline >25% & to a value >100 bpm | 3 | 0 | 2 | 1 |
| HR: Decrease from baseline >25% & to a value <60 bpm | 14 | 0 | 7 | 0 |
| PR: Increase from baseline >25% & to a value >200 ms | 1 | 0 | 2 | 0 |
| QRS: Increase from baseline >25% & to a value >110 ms | 0 | 0 | 0 | 0 |
| QT: Increase from baseline >30 ms | 24 | 0 | 9 | 0 |
| QT: Increase from baseline >60 ms | 2 | 0 | 0 | 0 |
| QT: New Interval >450 ms | 3 | — | 3 | 0 |
| QT: New Interval >480 ms | 1 | 0 | 0 | 0 |
| QT: New Interval >500 ms | 0 | 0 | 0 | 0 |
| QTcF: Increase from baseline >30 ms | 11 | 0 | 2 | 1 |
| QTcF: Increase from baseline >60 ms | 0 | 0 | 0 | 0 |
| QTcF: New Interval >450 ms | 14 | 0 | 3 | 0 |
| QTcF: New Interval >480 ms | 0 | 0 | 0 | 0 |
| QTcF: New Interval >500 ms | 0 | 0 | 0 | 0 |
In this outcome measure number of participants with at least 1 dose interruption for encorafenib and binimetinib were reported.
| Participants | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Encorafenib | 46 | 40 |
| Binimetinib | 44 | 41 |
In this outcome measure number of participants with at least 1 dose interruption for encorafenib, binimetinib, and each third combination agent were reported.
| Participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| Encorafenib | 14 | 0 | 4 | 2 |
| Binimetinib | 13 | 0 | 5 | 3 |
| Ribociclib | 11 | — | — | — |
| Infigratinib | — | 0 | — | — |
| Capmatinib | — | — | 5 | — |
| Buparlisib | — | — | — | 2 |
In this outcome measure number of participants with at least 1 dose reduction for encorafenib and binimetinib were reported.
| Participants | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Encorafenib | 9 | 14 |
| Binimetinib | 32 | 28 |
In this outcome measure number of participants with at least 1 dose reduction for encorafenib, binimetinib, and each third combination agent were reported.
| Participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| Encorafenib | 1 | 0 | 0 | 1 |
| Binimetinib | 11 | 0 | 5 | 3 |
| Ribociclib | 1 | — | — | — |
| Infigratinib | — | 0 | — | — |
| Capmatinib | — | — | 7 | — |
| Buparlisib | — | — | — | 1 |
Dose intensity across all cycles = cumulative dose/duration of exposure. Treatment cycle for encorafenib and binimetinib =21 days.
| Milligram per day | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Encorafenib | 425.311 ± 53.5392 | 408.711 ± 65.5297 |
| Binimetinib | 81.920 ± 13.0994 | 82.083 ± 10.9117 |
Dose intensity = cumulative dose/ duration of exposure. Treatment cycle = 21days for the combination treatment with buparlisib and capmatinib and 28 days for the combination treatment with ribociclib and infigratinib.
| Milligram per day | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| Encorafenib | 197.856 ± 42.6637 | 450.000 ± NA | 195.945 ± 8.4015 | 405.014 ± 102.5218 |
| Binimetinib | 79.749 ± 14.7267 | 90.000 ± NA | 87.373 ± 3.6593 | 78.791 ± 20.1538 |
| Ribociclib | 486.628 ± 79.4485 | — | — | — |
| Infigratinib | — | 60.227 ± NA | — | — |
| Capmatinib | — | — | 579.519 ± 259.1157 | — |
| Buparlisib | — | — | — | 72.206 ± 15.7019 |
PFS was defined as the time from the start date of study drug in Part I until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.
| Months | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Progression-Free Survival (PFS): Part I | 11.1 (8.1 to 15.0) | 3.3 (2.1 to 4.7) |
PFS was defined as the time from the start date of study drug in Part II until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.
| Months | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| PFS: Part II | 2.1 (1.7 to 2.1) | 2.1 (NA to NA) | 2.1 (1.0 to 3.7) | 1.4 (0.4 to NA) |
DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.
| Months | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Duration of Response (DOR): Part I | 10.9 (8.1 to 14.1) | 5.6 (3.9 to 13.0) |
DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.
| Months | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| DOR: Part II | 2.1 (NA to NA) | — | — | — |
TTR was defined as the time between the start date of study drug in Part I and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.
| Months | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Time to Response (TTR): Part I | 1.4 (1.38 to 1.41) | 0.72 (0.72 to 0.82) |
TTR was defined as the time between the start date of study drug in Part II and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.
| Months | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| TTR: Part II | 4.1 (NA to NA) | — | — | — |
DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Percentage of participants | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Disease Control Rate (DCR): Part I | 92.0 (83.4 to 97.0) | 42.2 (31.4 to 53.5) |
DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Percentage of participants | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| DCR: Part II | 26.3 (13.4 to 43.1) | 0 (NA to NA) | 15.4 (1.9 to 45.4) | 16.7 (0.4 to 64.1) |
OS was defined as the time from the start date of study treatment (3rd agent combined with encorafenib and binimetinib) to date of death due to any cause. If a participant was not known to have died, survival was censored at the date of last known date participant alive. Kaplan Meier method used for estimation.
| Months | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|
| Overall Survival (OS): Part II | 10.4 (6.0 to 16.7) | 20.8 (NA to NA) | 5.6 (1.7 to NA) | 2.5 (0.4 to NA) |
Number of participants with multiple alterations in genomic biomarkers like biomarker BRAF, CCND1, CDK4, EGFR, FGFR1, FGFR4, KRAS, MET, NRAS, PIK3CA, and PTEN were reported and alterations included copy number variant/copy number ratio (CNV/CNR), rearrangement, short variant. It was not necessary that all biomarkers had all alterations. Baseline = last non-missing value prior to the first dose of study treatment.
| Participants | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| BRAF: CNV/CNR at Baseline | 4 | 9 |
| BRAF: CNV/CNR at EOT | 2 | 3 |
| BRAF: Rearrangement/Genomic Position at Baseline chr7:140482508-140482692 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at Baseline chr7:140487121-140487285 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at Baseline chr7:140487916-140488167 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at Baseline chr7:140488878-140489055 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at Baseline cchr7:140489413-140489576 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at Baseline chr7:140490446-140490656 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at Baseline chr7:140491528-140491878 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at Baseline chr7:140491580-140491878 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at Baseline chr7:140492969-140493301 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140481691-140482150 | 1 | 0 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140482057-140482467 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140482081-140482482 | 1 | 0 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140482088-140482296 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140482167-140482382 | 1 | 0 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140482495-140482731 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140482644-140482867 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140483058-140483257 | 1 | 0 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140486136-140486408 | 1 | 0 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140486274-140486561 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140489019-140489575 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140489219-140489431 | 1 | 0 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140489830-140490002 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140491411-140491879 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140492091-140492240 | 1 | 0 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140492379-140492708 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140492714-140492997 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140493601-140493951 | 0 | 1 |
| BRAF: Rearrangement/Genomic Position at EOT chr7:140493858-140494232 | 1 | 0 |
| BRAF: Short variant/amino acid change at Baseline V600E | 46 | 53 |
| BRAF: Short variant/amino acid change at Baseline V600G | 1 | 0 |
| BRAF: Short variant/amino acid change at Baseline V600K | 4 | 7 |
| BRAF: Short variant/amino acid change at Baseline V600R | 1 | 0 |
| BRAF: Short variant/amino acid change at EOT V600E | 18 | 19 |
| BRAF: Short variant/amino acid change at EOT V600K | 0 | 4 |
| BRAF: Short variant/amino acid change at EOT V600R | 1 | 0 |
| CCND1: CNV/CNR at Baseline | 1 | 0 |
| CDK4: CNV/CNR at Baseline | 3 | 2 |
| EGFR: CNV/CNR at Baseline | 1 | 3 |
| EGFR: CNV/CNR at EOT | 1 | 1 |
| FGFR1: CNV/CNR at Baseline | 1 | 0 |
| FGFR1: CNV/CNR at EOT | 1 | 0 |
| FGFR4: CNV/CNR at Baseline | 1 | 0 |
| KRAS: CNV/CNR at Baseline | 2 | 0 |
| MET: CNV/CNR at Baseline | 4 | 6 |
| MET: CNV/CNR at EOT | 3 | 5 |
| MET: Rearrangement/Genomic Position at EOT chr7:116321020-116321260 | 1 | 0 |
| NRAS: CNV/CNR at Baseline | 0 | 1 |
| PIK3CA: CNV/CNR at Baseline | 1 | 0 |
| PTEN: CNV/CNR at Baseline | 4 | 13 |
| PTEN: CNV/CNR at EOT | 5 | 10 |
| PTEN: Rearrangement/Genomic Position at EOT chr10:89720538-89720776 | 0 | 1 |
In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5) and end of treatment (EOT). Maximum treatment exposure for Part I was of 403.7 weeks.
| Nanogram per milliliter | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| C1 D1, 1.5 hr | 4820 ± 114.2 | 4480 ± 124.4 |
| C1 D15, Pre-dose | 10.0 ± 81.6 | 13.8 ± 104.4 |
| C1 D15, 1.5 hr | 2470 ± 116.7 | 2910 ± 91.6 |
| C2 D8, Pre-dose | 9.96 ± 81.7 | 14.7 ± 117.5 |
| C2 D21, Pre-dose | 9.04 ± 84.2 | 15.6 ± 156.3 |
| C3 D15, Pre-dose | 8.43 ± 82.3 | 11.2 ± 114.3 |
| C4 D15, Pre-dose | 9.21 ± 100.3 | 12.3 ± 108.9 |
| C5 D15, Pre-dose | 8.84 ± 59.4 | 11.9 ± 72.7 |
| EOT | 19.6 ± 399.9 | 34.5 ± 890.3 |
In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 16 (D16), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5). Maximum treatment exposure for Part II was of 97.0 weeks.
| Nanogram per milliliter | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 D1: 1.5 hrs | — | 3430 ± 17.6 | 1860 ± NA | 1130 ± 3.8 | 3750 ± NA | 1770 ± 62.9 | 878 ± NA | 2030 ± NA | 847 ± 28.1 | — | 1600 ± 85.6 |
| C1 D1: 4 hrs | — | — | — | — | — | — | 238 ± NA | 297 ± NA | 626 ± 65.7 | — | 596 ± 51.1 |
| C1 D8: Pre-dose | 8.97 ± 89.0 | 21.3 ± 150.6 | 12.4 ± NA | 10.3 ± 54.4 | 6.21 ± NA | 11.7 ± 56.4 | 12.5 ± NA | 15.2 ± NA | 9.39 ± 15.9 | 7.15 ± NA | 16.2 ± 116.1 |
| C1 D15: Pre-dose | 11.2 ± 106.3 | 18.6 ± 159.4 | 7.74 ± NA | 9.95 ± 40.1 | 7.95 ± NA | 13.5 ± 35.0 | 9.28 ± NA | 10.3 ± NA | 7.75 ± 37.3 | — | 20.9 ± 188.5 |
| C1 D15: 0.5 hr | 437 ± 228.2 | 625 ± 19.5 | 1690 ± NA | 262 ± 345.5 | 139 ± NA | 127 ± 216.1 | 8.55 ± NA | 601 ± NA | 473 ± 1248.5 | — | 175 ± 252.7 |
| C1 D15: 1.5 hrs | 3050 ± 59.6 | 2150 ± 54.6 | 2100 ± NA | 1550 ± 62.4 | 2890 ± NA | 2500 ± 27.9 | 366 ± NA | 1960 ± NA | 1450 ± 3.9 | — | 1850 ± 69.7 |
| C1 D15: 2.5 hrs | 1420 ± 39.6 | 1320 ± 30.0 | 1020 ± NA | 808 ± 55.0 | — | 1550 ± 34.4 | 622 ± NA | 981 ± NA | 686 ± NA | — | 1510 ± 48.2 |
| C1 D15: 4 hrs | 649 ± 37.5 | 770 ± 6.2 | 397 ± NA | 453 ± 24.3 | 1160 ± NA | 667 ± 20.4 | 389 ± NA | — | 478 ± 39.6 | — | 1020 ± 34.3 |
| C1 D15: 6 hrs | 246 ± 94.6 | 433 ± 45.0 | 211 ± NA | 165 ± 68.8 | 266 ± NA | 317 ± 26.8 | 209 ± NA | 199 ± NA | 203 ± 11.1 | — | 567 ± 51.5 |
| C1 D15: 8 hrs | 180 ± 94.5 | 276 ± 103.8 | — | 115 ± 55.4 | 257 ± NA | 217 ± 34.5 | 142 ± NA | 132 ± NA | 109 ± 2.6 | — | 412 ± 62.3 |
| C1 D16: 24 hrs | 11.3 ± 45.3 | 25.1 ± 2066.8 | 6.76 ± NA | 8.10 ± 43.1 | 5.20 ± NA | 15.0 ± 20.9 | 10.7 ± NA | 7.85 ± NA | 10.8 ± 106.1 | — | 22.8 ± 199.0 |
| C1 D21: Pre-dose | — | — | 10.4 ± NA | — | — | — | 13.6 ± NA | 13.9 ± NA | 12.4 ± 60.4 | 20.3 ± NA | 17.5 ± 106.4 |
| C2 D1: Pre-dose | 13.5 ± 193.0 | 32.6 ± 202.9 | 12.7 ± NA | 19.9 ± 210.5 | 2.91 ± NA | 14.0 ± 30.3 | 8.50 ± NA | 82.5 ± NA | 8.19 ± 42.2 | 19.2 ± NA | 11.9 ± 100.9 |
| C2 D15: Pre-dose | 41.3 ± NA | 15.6 ± NA | 13.9 ± NA | 9.68 ± 36.5 | — | 8.49 ± 70.5 | 11.1 ± NA | 16.5 ± NA | 12.3 ± 24.3 | 8.95 ± NA | 21.3 ± 115.3 |
| C3 D1: Pre-dose | 13.9 ± NA | — | 20.5 ± NA | 23.2 ± 33.1 | — | 10.1 ± 72.1 | — | NA ± NA | — | — | 9.34 ± 125.7 |
| C4 D1: Pre-dose | 30.2 ± NA | — | — | — | — | 12.5 ± 11.4 | 5.95 ± NA | 7.28 ± NA | — | — | 13.1 ± 21.8 |
| C5 D1: Pre-dose | 749 ± NA | — | — | — | — | — | 10.7 ± NA | 9.84 ± NA | — | — | 9.15 ± 44.0 |
| EOT | 1.77 ± NA | NA ± NA | 14.3 ± NA | NA ± NA | NA ± NA | 13.9 ± 66.6 | 8.24 ± NA | 6.81 ± NA | 24.5 ± 259.8 | NA ± NA | 16.6 ± 265.0 |
AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part I was of 403.7 weeks.
| Nanogram per milliliter | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) |
|---|---|---|
| Binimetinib: C1 D1, 1.5 hr | 551 ± 88.8 | 482 ± 73.4 |
| Binimetinib: C1 D15, Pre-dose | 40.3 ± 63.5 | 43.3 ± 72.9 |
| Binimetinib: C1 D15, 1.5 hr | 461 ± 70.2 | 451 ± 50.2 |
| Binimetinib: C2 D8, Pre-dose | 39.9 ± 58.8 | 44.8 ± 73.0 |
| Binimetinib: C2 D21, Pre-dose | 38.9 ± 54.9 | 53.1 ± 78.2 |
| Binimetinib: C3 D15, Pre-dose | 41.9 ± 60.4 | 38.7 ± 94.6 |
| Binimetinib: C4 D15, Pre-dose | 36.2 ± 68.6 | 38.8 ± 57.4 |
| Binimetinib: C5 D15, Pre-dose | 41.3 ± 55.7 | 39.2 ± 76.1 |
| Binimetinib: EOT | 33.2 ± 179.4 | 52.8 ± 180.4 |
| AR00426032: C1 D1, 1.5 hr | 57.6 ± 93.5 | 47.5 ± 101.6 |
| AR00426032: C1 D15, Pre-dose | 4.13 ± 70.8 | 4.50 ± 64.0 |
| AR00426032: C1 D15, 1.5 hr | 30.6 ± 110.9 | 31.9 ± 84.0 |
| AR00426032: C2 D8, Pre-dose | 3.63 ± 60.2 | 4.17 ± 88.1 |
| AR00426032: C2 D21, Pre-dose | 4.11 ± 61.0 | 4.39 ± 80.2 |
| AR00426032: C3 D15, Pre-dose | 3.71 ± 59.5 | 3.90 ± 60.6 |
| AR00426032: C4 D15, Pre-dose | 3.48 ± 65.8 | 3.81 ± 56.9 |
| AR00426032: C5 D15, Pre-dose | 3.77 ± 66.9 | 3.36 ± 67.3 |
| AR00426032: EOT | 4.09 ± 90.8 | 5.88 ± 118.0 |
AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part II was of 97.0 weeks.
| Nanogram per milliliter | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Binimetinib, C1 D1: 1.5 hrs | — | 410 ± 48.8 | 416 ± NA | 313 ± 25.6 | 1100 ± NA | 508 ± 130.2 | 396 ± NA | 649 ± NA | 273 ± 24.6 | — | 446 ± 59.8 | 522 ± NA | 1230 ± NA |
| Binimetinib, C1 D1: 4 hrs | — | — | — | — | — | — | 152 ± NA | 106 ± NA | 129 ± 25.8 | — | 215 ± 44.5 | 99.5 ± NA | — |
| Binimetinib, C1 D8: Pre-dose | 41.6 ± 21.7 | 51.1 ± 9.7 | 46.0 ± NA | 74.6 ± 34.5 | 27.2 ± NA | 67.4 ± 63.1 | 63.0 ± NA | 31.5 ± NA | 25.1 ± 1.7 | 27.2 ± NA | 51.0 ± 67.8 | 37.3 ± NA | — |
| Binimetinib, C1 D15: Pre-dose | 32.0 ± 17.1 | 39.1 ± 57.4 | 33.9 ± NA | 85.6 ± 53.7 | 47.3 ± NA | 50.9 ± 34.4 | 54.3 ± NA | 28.3 ± NA | 21.1 ± 23.7 | — | 48.2 ± 70.0 | 36.2 ± NA | — |
| Binimetinib, C1 D15: 0.5 hr | 150 ± 36.1 | 143 ± 496.2 | 315 ± NA | 430 ± 26.8 | 401 ± NA | 180 ± 91.5 | 229 ± NA | 389 ± NA | 161 ± 54.7 | — | 158 ± 90.1 | — | — |
| Binimetinib, C1 D15: 1.5 hrs | 386 ± 41.1 | 187 ± 351.0 | 413 ± NA | 489 ± 27.1 | 797 ± NA | 734 ± 45.6 | 261 ± NA | 520 ± NA | 313 ± 15.9 | — | 437 ± 46.5 | — | — |
| Binimetinib, C1 D15: 2.5 hrs | 250 ± 17.1 | 143 ± 172.4 | 235 ± NA | 295 ± 29.7 | — | 491 ± 38.0 | 207 ± NA | 331 ± NA | 154 ± NA | — | 380 ± 31.2 | 178 ± NA | — |
| Binimetinib, C1 D15: 4 hrs | 147 ± 21.4 | 125 ± 62.1 | 98.0 ± NA | 166 ± 48.9 | 264 ± NA | 266 ± 32.5 | 130 ± NA | — | 98.0 ± 60.0 | — | 241 ± 28.6 | — | — |
| Binimetinib, C1 D15: 6 hrs | 79.0 ± 36.1 | 97.3 ± 32.8 | 55.8 ± NA | 106 ± 53.3 | 112 ± NA | 141 ± 15.1 | 167 ± NA | 77.4 ± NA | 53.3 ± 36.2 | — | 134 ± 46.5 | — | — |
| Binimetinib, C1 D15: 8 hrs | 74.9 ± 34.7 | 59.7 ± 12.6 | — | 107 ± 40.9 | 132 ± NA | 102 ± 12.4 | 116 ± NA | 65.5 ± NA | 42.2 ± 39.2 | — | 109 ± 54.8 | — | — |
| Binimetinib, C1 D16: 24 hrs | 44.1 ± 19.1 | 30.2 ± 59.2 | 42.1 ± NA | 63.2 ± 64.0 | 17.6 ± NA | 55.9 ± 54.0 | 78.3 ± NA | 29.8 ± NA | 23.1 ± 5.2 | — | 55.2 ± 66.0 | 40.5 ± NA | — |
| Binimetinib, C1 D21: Pre-dose | — | — | 34.0 ± NA | — | — | — | 40.4 ± NA | 38.8 ± NA | 13.6 ± 80.7 | 19.6 ± NA | 63.2 ± 51.0 | 35.3 ± NA | 8.91 ± NA |
| Binimetinib, C2 D1: Pre-dose | 38.8 ± 62.5 | 42.7 ± 27.8 | 40.5 ± NA | 118 ± 120.1 | 24.6 ± NA | 54.2 ± 32.4 | 58.3 ± NA | 174 ± NA | 23.3 ± 20.2 | 58.3 ± NA | 46.0 ± 71.2 | 22.4 ± NA | 54.1 ± NA |
| Binimetinib, C2 D15: Pre-dose | 63.7 ± NA | 73.0 ± NA | 63.9 ± NA | 40.9 ± 50.8 | 18.9 ± NA | 49.8 ± 21.2 | 63.1 ± NA | 19.4 ± NA | 15.2 ± 18.2 | 14.1 ± NA | 58.4 ± 68.3 | 27.3 ± NA | 34.9 ± NA |
| Binimetinib, C3 D1: Pre-dose | 50.0 ± NA | — | 47.2 ± NA | 37.8 ± 189.6 | — | 41.9 ± 49.0 | 53.4 ± NA | 4.82 ± NA | — | — | 45.0 ± 91.8 | 42.0 ± NA | — |
| Binimetinib, C4 D1: Pre-dose | 46.1 ± NA | — | — | — | — | 53.8 ± 10.6 | 63.6 ± NA | 40.9 ± NA | — | — | 77.5 ± 32.1 | — | — |
| Binimetinib, C5 D1: Pre-dose | 60.0 ± NA | — | — | — | — | — | 42.3 ± NA | 28.5 ± NA | — | — | 73.8 ± 25.7 | — | — |
| Binimetinib, EOT | NA ± NA | NA ± NA | 36.3 | NA ± NA | NA ± NA | 52.1 ± 18.3 | 41.0 ± NA | 32.3 ± NA | 13.8 ± 205.5 | NA ± NA | 29.0 ± 179.7 | — | — |
| AR00426032, C1 D1: 1.5 hrs | — | 22.4 ± 200.6 | 12.9 ± NA | 11.4 ± 85.7 | — | 35.9 ± 274.1 | — | 22.1 ± NA | 8.05 ± 68.9 | — | 19.4 ± 99.3 | 16.3 ± NA | 64.6 ± NA |
| AR00426032, C1 D1: 4 hrs | — | — | — | — | — | — | 9.40 ± NA | 4.09 ± NA | 6.71 ± 145.3 | — | 12.3 ± 75.3 | 4.61 ± NA | — |
| AR00426032, C1 D8: Pre-dose | 3.98 ± 31.9 | 2.95 ± 165.3 | 1.21 ± NA | 7.10 ± 122.1 | — | 6.34 ± 54.5 | 6.15 ± NA | 1.10 ± NA | 1.73 ± 48.7 | 2.09 ± NA | 5.50 ± 62.6 | 2.14 ± NA | — |
| AR00426032, C1 D15: Pre-dose | 3.14 ± 74.5 | 3.80 ± 111.9 | 1.21 ± NA | 11.5 ± 39.5 | 4.36 ± NA | 5.45 ± 42.2 | 4.16 ± NA | NA ± NA | 3.81 ± NA | — | 4.19 ± 79.2 | 1.09 ± NA | — |
| AR00426032, C1 D15: 0.5 hr | 6.66 ± 43.2 | 7.43 ± 455.1 | 8.21 ± NA | 13.1 ± 97.8 | 11.4 ± NA | 9.80 ± 75.7 | 7.31 ± NA | 4.35 ± NA | 6.16 ± 490.6 | — | 7.81 ± 119.0 | — | — |
| AR00426032, C1 D15: 1.5 hrs | 24.9 ± 92.2 | 13.2 ± 1550.1 | 15.8 ± NA | 27.9 ± 85.6 | — | 41.1 ± 25.7 | 12.9 ± NA | 12.6 ± NA | 16.1 ± 151.9 | — | 18.3 ± 135.9 | — | — |
| AR00426032, C1 D15: 2.5 hrs | 18.5 ± 77.0 | 11.3 ± 447.2 | 7.75 ± NA | 18.5 ± 88.4 | — | 34.3 ± 51.3 | 9.71 ± NA | 8.51 ± NA | 16.2 ± NA | — | 18.5 ± 81.2 | 4.73 ± NA | — |
| AR00426032, C1 D15: 4 hrs | 11.8 ± 40.3 | 9.98 ± 142.4 | 3.15 ± NA | 9.46 ± 142.7 | 22.6 ± NA | 19.3 ± 76.9 | 6.76 ± NA | — | 5.21 ± 81.9 | — | 12.2 ± 78.7 | — | — |
| AR00426032, C1 D15: 6 hrs | 6.86 ± 61.8 | 7.66 ± 117.7 | 1.82 ± NA | 6.90 ± 142.3 | 8.89 ± NA | 9.66 ± 71.5 | 5.82 ± NA | 2.52 ± NA | 3.07 ± 95.0 | — | 7.41 ± 80.2 | — | — |
| AR00426032b, C1 D15: 8 hrs | 5.94 ± 76.7 | 5.24 ± 70.7 | — | 6.49 ± 124.9 | 8.06 ± NA | 8.87 ± 76.5 | 5.12 ± NA | 1.95 ± NA | 2.67 ± 72.9 | — | 6.73 ± 75.0 | — | — |
| AR00426032, C1 D16: 24 hrs | 3.99 ± 61.8 | 2.92 ± 159.3 | 1.27 ± NA | 7.79 ± 87.5 | 1.44 ± NA | 4.75 ± 25.4 | 6.53 ± NA | 1.08 ± NA | 3.19 ± NA | — | 4.70 ± 80.2 | 1.56 ± NA | — |
| AR00426032, C1 D21: Pre-dose | — | — | NA ± NA | — | — | — | 3.66 ± NA | 1.47 ± NA | 3.18 ± NA | 1.13 ± NA | 6.64 ± 56.1 | 1.65 ± NA | 3.11 ± NA |
| AR00426032, C2 D1: Pre-dose | 6.23 ± 82.0 | 3.51 ± 36.8 | NA ± NA | 13.5 ± 116.8 | — | 5.71 ± 44.2 | 4.32 ± NA | 2.06 ± NA | 4.09 ± NA | 3.99 ± NA | 4.03 ± 58.1 | NA ± NA | 17.8 ± NA |
| AR00426032, C2 D15: Pre-dose | 9.97 ± NA | 7.52 ± NA | 1.07 ± NA | 3.27 ± 65.1 | 1.74 ± NA | 4.23 ± 62.5 | 8.54 ± NA | 1.63 ± NA | 1.99 ± NA | 1.19 ± NA | 5.69 ± 57.0 | 1.33 ± NA | 3.74 ± NA |
| AR00426032 C3 D1: Pre-dose | 9.74 ± NA | — | NA ± NA | 6.15 ± NA | — | 4.35 ± 42.3 | 4.50 ± NA | 1.09 ± NA | — | — | 4.46 ± 70.2 | 1.73 ± NA | — |
| AR00426032, C4 D1: Pre-dose | 7.10 ± NA | — | — | — | — | 5.70 ± 11.8 | 5.43 ± NA | 2.78 ± NA | — | — | 5.78 ± 83.0 | — | — |
| AR00426032, C5 D1: Pre-dose | 6.05 ± NA | — | — | — | — | — | 8.89 ± NA | 1.36 ± NA | — | — | 6.11 ± 67.8 | — | — |
| AR00426032, EOT | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 6.68 ± 80.1 | 3.77 ± NA | 1.48 ± NA | 3.65 ± NA | NA ± NA | 4.24 ± 85.5 | — | — |
LEQ803 is metabolite of ribociclib. Maximum treatment exposure for Part II was of 97.0 weeks.
| Nanogram per milliliter | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|
| Ribociclib, C1 D1: 1.5 hrs | 220 ± NA | 117 ± NA | 107 ± 40.6 | — | 230 ± 119.7 | 185 ± NA | 784 ± NA |
| Ribociclib, C1 D1: 4 hrs | 213 ± NA | 84.5 ± NA | 205 ± 96.0 | — | 354 ± 58.5 | 268 ± NA | — |
| Ribociclib, C1 D8: Pre-dose | 77.4 ± NA | 32.3 ± NA | 30.7 ± 33.5 | — | 100 ± 49.9 | 80.5 ± NA | 127 ± NA |
| Ribociclib, C1 D15: Pre-dose | 98.4 ± NA | 28.2 ± NA | 30.7 ± 24.9 | — | 104 ± 54.2 | 64.7 | — |
| Ribociclib, C1 D15: 0.5 hr | 86.1 ± NA | 59.7 ± NA | 35.4 ± 66.6 | — | 179 ± 65.0 | — | — |
| Ribociclib, C1 D15: 1.5 hrs | 204 ± NA | 95.9 ± NA | 200 ± 240.3 | — | 508 ± 95.2 | — | — |
| Ribociclib, C1 D15: 2.5 hrs | 321 ± NA | 126 ± NA | 718 ± NA | — | 627 ± 68.3 | 393 ± NA | — |
| Ribociclib, C1 D15: 4 hrs | 368 ± NA | — | 341 ± 42.9 | — | 707 ± 62.2 | — | — |
| Ribociclib, C1 D15: 6 hrs | 434 ± NA | 109 ± NA | 239 ± 37.2 | — | 578 ± 55.9 | — | — |
| Ribociclib, C1 D15: 8 hrs | 311 ± NA | 83.6 ± NA | 182 ± 27.1 | — | 477 ± 55.2 | — | — |
| Ribociclib, C1 D16: 24 hrs | 94.0 ± NA | 25.6 ± NA | 52.7 ± 90.4 | — | 120 ± 64.9 | 91.8 ± NA | — |
| Ribociclib, C1 D21: Pre-dose | 105 ± NA | — | 102 ± NA | — | 112 ± 75.8 | 69.9 ± NA | 115 ± NA |
| Ribociclib, C2 D1: Pre-dose | NA ± NA | 19.5 ± NA | 1.59 ± NA | 1.07 ± NA | 7.00 ± 377.8 | — | 132 ± NA |
| Ribociclib, C2 D15: Pre-dose | 103 ± NA | 41.5 ± NA | 53.7 ± 51.2 | 36.0 ± NA | 107 ± 59.4 | 113 ± NA | 102 ± NA |
| Ribociclib, C3 D1: Pre-dose | 1.16 ± NA | NA ± NA | — | — | 4.06 ± 172.4 | — | — |
| Ribociclib, C4 D1: Pre-dose | 1.22 ± NA | — | — | — | 1.59 ± 31.6 | — | — |
| Ribociclib, C5 D1: Pre-dose | — | — | — | — | 2.16 ± 35.5 | — | — |
| Ribociclib, EOT | 1.94 ± NA | 60.3 ± NA | 1.49 ± NA | 45.8 ± NA | 29.0 ± 292.1 | — | 22.8 ± NA |
| LEQ803, C1 D1: 1.5 hrs | 57.1 ± NA | 70.2 ± NA | 68.2 ± 2.4 | — | 47.5 ± 97.4 | 59.0 ± NA | 63.6 ± NA |
| LEQ803, C1 D1: 4 hrs | 65.2 ± NA | 50.8 ± NA | 73.5 ± 20.4 | — | 81.1 ± 55.6 | 63.2 ± NA | — |
| LEQ803, C1 D8: Pre-dose | 64.3 ± NA | 49.3 ± NA | 38.1 ± 9.1 | — | 53.7 ± 36.5 | 47.2 | 71.2 |
| LEQ803, C1 D15: Pre-dose | 76.0 ± NA | 37.1 ± NA | 32.9 ± 25.7 | — | 55.1 ± 33.9 | 49.2 ± NA | — |
| LEQ803, C1 D15: 0.5 hr | 75.5 ± NA | 39.5 ± NA | 32.1 ± 0.7 | — | 60.8 ± 36.9 | — | — |
| LEQ803, C1 D15: 1.5 hrs | 92.3 ± NA | 72.6 ± NA | 82.7 ± 0.7 | — | 112 ± 46.9 | — | — |
| LEQ803, C1 D15: 2.5 hrs | 130 ± NA | 92.5 ± NA | 126 ± NA | — | 133 ± 45.4 | 137 ± NA | — |
| LEQ803, C1 D15: 4 hrs | 138 ± NA | — | 140 ± 23.4 | — | 152 ± 31.2 | — | — |
| LEQ803, C1 D15: 6 hrs | 175 ± NA | 90.2 ± NA | 111 ± 27.6 | — | 145 ± 27.2 | — | — |
| LEQ803, C1 D15: 8 hrs | 135 ± NA | 79.8 ± NA | 95.2 ± 50.1 | — | 128 ± 27.6 | — | — |
| LEQ803, C1 D16: 24 hrs | 84.5 ± NA | 46.8 ± NA | 42.5 ± 13.8 | — | 63.1 ± 36.1 | 59.6 ± NA | — |
| LEQ803, C1 D21: Pre-dose | 73.8 ± NA | — | 43.7 ± NA | — | 58.1 ± 39.1 | 52.9 ± NA | 80.2 ± NA |
| LEQ803, C2 D1: Pre-dose | 6.68 ± NA | 14.5 ± NA | 4.10 ± NA | 2.70 ± NA | 8.48 ± 154.5 | — | 80.8 ± NA |
| LEQ803, C2 D15: Pre-dose | 90.0 ± NA | 45.6 ± NA | 45.7 ± 6.8 | 28.0 ± NA | 58.3 ± 42.7 | 66.8 ± NA | 61.1 ± NA |
| LEQ803, C3 D1: Pre-dose | 7.88 ± NA | 2.75 ± NA | — | — | 7.57 ± 61.4 | — | — |
| LEQ803, C4 D1: Pre-dose | 7.19 ± NA | — | — | — | 5.72 ± 6.9 | — | — |
| LEQ803, C5 D1: Pre-dose | — | — | — | — | 6.07 ± 28.9 | — | — |
| LEQ803, EOT | 10.4 ± NA | 69.3 ± NA | 5.06 ± 4.6 | 23.5 ± NA | 20.6 ± 152.2 | — | 31.2 ± NA |
BHS697 and CQM157 are metabolites of infigratinib. Maximum treatment exposure for Part II was of 97.0 weeks.
| Nanogram per milliliter | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg |
|---|---|
| Infigratinib, C1 D1: 1.5 hrs | 15.0 ± NA |
| Infigratinib, C1 D8: Pre-dose | 2.67 ± NA |
| Infigratinib, C1 D15: Pre-dose | 2.49 ± NA |
| Infigratinib, C1 D15: 0.5 hr | 3.39 ± NA |
| Infigratinib, C1 D15: 1.5 hrs | 15.2 ± NA |
| Infigratinib, C1 D15: 2.5 hrs | 27.5 ± NA |
| Infigratinib, C1 D15: 4 hrs | 24.7 ± NA |
| Infigratinib, C1 D15: 6 hrs | 20.5 ± NA |
| Infigratinib, C1 D21: Pre-dose | 2.05 ± NA |
| Infigratinib, C2 D1: Pre-dose | NA ± NA |
| Infigratinib, C2 D15: Pre-dose | 4.65 ± NA |
| Infigratinib, C3 D1: Pre-dose | NA ± NA |
| Infigratinib, EOT | 2.42 ± NA |
| BHS697, C1 D1: 1.5 hrs | 4.83 ± NA |
| BHS697, C1 D8: Pre-dose | 2.17 ± NA |
| BHS697, C1 D15: Pre-dose | 1.64 ± NA |
| BHS697, C1 D15: 0.5 hr | 2.14 ± NA |
| BHS697, C1 D15: 1.5 hrs | 6.83 ± NA |
| BHS697, C1 D15: 2.5 hrs | 8.53 ± NA |
| BHS697, C1 D15: 4 hrs | 6.89 ± NA |
| BHS697, C1 D15: 6 hrs | 5.57 ± NA |
| BHS697, C1 D21: Pre-dose | 1.37 ± NA |
| BHS697, C2 D1: Pre-dose | NA ± NA |
| BHS697, C2 D15: Pre-dose | 2.83 ± NA |
| BHS697, C3 D1: Pre-dose | NA ± NA |
| BHS697, EOT | 1.69 ± NA |
| CQM157, C1 D1: 1.5 hrs | 13.0 ± NA |
| CQM157, C1 D8: Pre-dose | 14.1 ± NA |
| CQM157, C1 D15: Pre-dose | 11.1 ± NA |
| CQM157, C1 D15: 0.5 hr | 12.0 ± NA |
| CQM157, C1 D15: 1.5 hrs | 21.3 ± NA |
| CQM157, C1 D15: 2.5 hrs | 28.3 ± NA |
| CQM157, C1 D15: 4 hrs | 25.0 ± NA |
| CQM157, C1 D15: 6 hrs | 32.2 ± NA |
| CQM157, C1 D21: Pre-dose | 9.65 ± NA |
| CQM157, C2 D1: Pre-dose | NA ± NA |
| CQM157, C2 D15: Pre-dose | 15.5 ± NA |
| CQM157, C3 D1: Pre-dose | NA ± NA |
| CQM157, EOT | 11.9 ± NA |
Maximum treatment exposure for Part II was of 97.0 weeks.
| Nanogram per milliliter | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg |
|---|---|---|---|
| C1 D1: 1.5 hrs | 362 ± 268.6 | 3600 ± NA | 715 ± 133.2 |
| C1 D8: Pre-dose | 74.3 ± 97.2 | 44.4 ± NA | 129 ± 49.4 |
| C1 D15: Pre-dose | 89.3 ± 35.7 | 71.4 ± NA | 173 ± 41.2 |
| C1 D15: 0.5 hr | 196 ± 103.8 | 1880 ± NA | 314 ± 49.0 |
| C1 D15: 1.5 hrs | 636 ± 78.2 | 3670 ± NA | 1830 ± 38.3 |
| C1 D15: 2.5 hrs | 545 ± 81.2 | — | 1530 ± 18.4 |
| C1 D15: 4 hrs | 401 ± 17.3 | 1230 ± NA | 950 ± 39.1 |
| C1 D15: 6 hrs | 157 ± 63.2 | 264 ± NA | 487 ± 23.3 |
| C1 D15: 8 hrs | 120 ± 50.0 | 268 ± NA | 390 ± 10.5 |
| C1 D16: 24 hrs | 79.6 ± 103.1 | 58.1 ± NA | 269 ± 68.7 |
| C2 D1: Pre-dose | 151 ± 107.6 | 38.7 ± NA | 227 ± 42.0 |
| C2 D15: Pre-dose | 65.2 ± 31.0 | 50.5 ± NA | 166 ± 80.9 |
| C3 D1: Pre-dose | 114 ± 113.4 | — | 96.5 ± 17.9 |
| C4 D1: Pre-dose | — | — | 175 ± 44.8 |
| C5 D1: Pre-dose | — | 41.8 ± NA | — |
| EOT | NA ± NA | NA ± NA | 65.4 ± 155.0 |
Maximum treatment exposure for Part II was of 97.0 weeks.
| Nanogram per milliliter | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg |
|---|---|---|
| C1 D1: 1.5 hrs | 213 ± NA | 213 ± NA |
| C1 D8: Pre-dose | 45.0 ± 75.2 | 119 ± 3.6 |
| C1 D15: Pre-dose | 49.7 ± 115.9 | 97.3 ± 16.2 |
| C1 D15: 0.5 hr | 139 ± 13.4 | 229 ± 21.5 |
| C1 D15: 1.5 hrs | 266 ± 51.5 | 312 ± 10.9 |
| C1 D15: 2.5 hrs | 176 ± 42.2 | 268 ± 11.9 |
| C1 D15: 4 hrs | 115 ± 44.0 | 235 ± 39.4 |
| C1 D15: 6 hrs | 94.2 ± 40.0 | 171 ± 26.4 |
| C1 D15: 8 hrs | 87.4 ± 63.9 | 111 ± 25.5 |
| C1 D16: 24 hrs | 41.8 ± 82.9 | 101 ± 1.4 |
| C2 D1: Pre-dose | 54.7 ± 134.9 | 110 ± 51.2 |
| C2 D15: Pre-dose | 99.3 ± NA | 138 ± NA |
| C3 D1: Pre-dose | 81.2 ± NA | — |
| C4 D1: Pre-dose | 73.2 ± NA | — |
| C5 D1: Pre-dose | 122 ± NA | — |
| EOT | 1.84 ± 53.4 | NA ± NA |
| Nanogram per milliliter | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encorafenib | 3060 ± 58.8 | 2150 ± 54.6 | 2100 ± NA | 1600 ± 62.0 | 2890 ± NA | 2570 ± 23.0 | 622 ± NA | 1960 ± NA | 1860 ± 32.1 | 2010 ± NA | 2030 ± 40.6 | — |
| Binimetinib | 386 ± 41.1 | 221 ± 237.6 | 413 ± NA | 515 ± 17.0 | 797 ± NA | 858 ± 13.0 | 261 ± NA | 520 ± NA | 313 ± 15.9 | 584 ± NA | 489 ± 31.3 | 291 ± NA |
| Binimetinib metabolite, AR00426032 | 24.9 ± 92.2 | 18.1 ± 591.2 | 15.8 ± NA | 27.9 ± 85.6 | 22.6 ± NA | 47.1 ± 29.2 | 12.9 ± NA | 12.6 ± NA | 16.1 ± 151.9 | 19.4 ± NA | 23.7 ± 94.1 | 9.04 ± NA |
| Ribociclib | — | — | — | — | — | — | 434 ± NA | 126 ± NA | 428 ± 84.2 | 282 ± NA | 753 ± 70.6 | 597 ± NA |
| Ribociclib metabolite, LEQ803 | — | — | — | — | — | — | 175 ± NA | 93.2 ± NA | 144 ± 19.2 | 67.5 ± NA | 156 ± 36.2 | 138 ± NA |
| Infigratinib | — | — | 27.5 ± NA | — | — | — | — | — | — | — | — | — |
| Infigratinib metabolite, BHS697 | — | — | 8.53 ± NA | — | — | — | — | — | — | — | — | — |
| Infigratinib metabolite, CQM157 | — | — | 32.2 ± NA | — | — | — | — | — | — | — | — | — |
| Capmatinib | — | — | — | 722 ± 85.3 | 3670 ± NA | 1920 ± 31.8 | — | — | — | — | — | — |
| Buparlisib | 266 ± 51.5 | 312 ± 10.9 | — | — | — | — | — | — | — | — | — | — |
| Hour | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encorafenib | 1.33 (0.58 to 1.50) | 1.54 (1.50 to 1.58) | 1.50 (1.50 to 1.50) | 1.50 (0.50 to 1.53) | 1.50 (1.50 to 1.50) | 1.50 (1.50 to 2.50) | 2.37 (2.37 to 2.37) | 1.47 (1.47 to 1.47) | 1.00 (0.50 to 1.50) | 1.50 (1.50 to 1.50) | 1.58 (0.63 to 6.17) | — |
| Binimetinib | 1.50 (1.33 to 1.67) | 2.75 (1.50 to 4.00) | 1.50 (1.50 to 1.50) | 1.50 (0.50 to 1.58) | 1.50 (1.50 to 1.50) | 1.50 (1.50 to 2.50) | 1.38 (1.38 to 1.38) | 1.47 (1.47 to 1.47) | 1.50 (1.50 to 1.50) | 1.50 (1.50 to 1.50) | 1.58 (0.50 to 4.08) | 1.08 (1.08 to 1.08) |
| Binimetinib metabolite, AR00426032 | 1.50 (1.33 to 1.67) | 2.75 (1.50 to 4.00) | 1.50 (1.50 to 1.50) | 1.50 (1.50 to 1.58) | 4.00 (4.00 to 4.00) | 1.92 (1.50 to 2.50) | 1.38 (1.38 to 1.38) | 1.47 (1.47 to 1.47) | 1.50 (1.50 to 1.50) | 1.50 (1.50 to 1.50) | 1.65 (0.67 to 4.08) | 1.08 (1.08 to 1.08) |
| Ribociclib | — | — | — | — | — | — | 5.92 (5.92 to 5.92) | 2.45 (2.45 to 2.45) | 3.18 (2.33 to 4.03) | 1.50 (1.50 to 1.50) | 3.65 (1.50 to 6.00) | 0.50 (0.50 to 0.50) |
| Ribociclib metabolite, LEQ803 | — | — | — | — | — | — | 5.92 (5.92 to 5.92) | 4.98 (4.98 to 4.98) | 3.18 (2.33 to 4.03) | 1.50 (1.50 to 1.50) | 4.12 (1.55 to 7.00) | 1.08 (1.08 to 1.08) |
| Infigratinib | — | — | 2.50 (2.50 to 2.50) | — | — | — | — | — | — | — | — | — |
| Infigratinib metabolite, BHS697 | — | — | 2.50 (2.50 to 2.50) | — | — | — | — | — | — | — | — | — |
| Infigratinib metabolite, CQM157 | — | — | 5.75 (5.75 to 5.75) | — | — | — | — | — | — | — | — | — |
| Capmatinib | — | — | — | 1.53 (1.50 to 2.58) | 1.50 (1.50 to 1.50) | 1.50 (1.50 to 2.50) | — | — | — | — | — | — |
| Buparlisib | 1.50 (1.33 to 1.67) | 1.50 (1.50 to 1.50) | — | — | — | — | — | — | — | — | — | — |
| Hour*nanogram per milliliter | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encorafenib | 9080 ± 42.2 | 10100 ± 18.4 | 7420 ± NA | 4990 ± 42.6 | 10800 ± NA | 8570 ± 10.6 | 3490 ± NA | 6000 ± NA | 5740 ± 7.1 | 6200 ± NA | 11300 ± 41.1 | — |
| Binimetinib | 1580 ± 17.0 | 1220 ± 105.7 | 1260 ± NA | 2180 ± 29.4 | 3040 ± NA | 2760 ± 4.8 | 1700 ± NA | 1900 ± NA | 1140 ± 21.1 | 1740 ± NA | 2270 ± 29.5 | 1470 ± NA |
| Binimetinib metabolite, AR00426032 | 116 ± 66.8 | 94.4 ± 222.2 | 42.0 ± NA | 124 ± 113.9 | 135 ± NA | 182 ± 43.1 | 81.5 ± NA | 47.0 ± NA | 57.9 ± 128.5 | 66.9 ± NA | 115 ± 92.6 | 41.1 ± NA |
| Ribociclib | — | — | — | — | — | — | 5630 ± NA | 1650 ± NA | 3730 ± 62.5 | 2320 ± NA | 9230 ± 60.9 | 5960 ± NA |
| Ribociclib metabolite, LEQ803 | — | — | — | — | — | — | 2770 ± NA | 1640 ± NA | 1900 ± 24.9 | 930 ± NA | 2540 ± 31.3 | 2300 ± NA |
| Capmatinib | — | — | — | 3070 ± 52.6 | 12200 ± NA | 8420 ± 22.0 | — | — | — | — | — | — |
| Buparlisib | 2130 ± 54.6 | 3400 ± 18.5 | — | — | — | — | — | — | — | — | — | — |
Elimination half-life means the time required for the plasma concentration to decline by 50% during the elimination phase.
| Hour | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encorafenib | 3.75 ± 0.302 | 5.89 ± 4.32 | 3.57 ± NA | 4.18 ± 1.85 | 3.41 ± NA | 3.96 ± 0.233 | 4.27 ± NA | 3.75 ± NA | 4.32 ± 1.62 | 3.83 ± NA | 3.60 ± 0.711 | — |
| Binimetinib | 8.35 ± 3.52 | 3.48 ± 0.484 | 1.60 ± NA | 10.3 ± 6.29 | — | 5.88 ± 2.77 | 5.84 ± NA | 3.82 ± NA | 5.38 ± 3.39 | 10.9 ± NA | 4.13 ± 1.42 | — |
| Binimetinib metabolite, AR00426032 | 6.35 ± 1.21 | 4.14 ± 0.683 | 1.59 ± NA | 7.95 ± 4.03 | 2.86 ± NA | 5.64 ± 2.49 | — | 4.34 ± NA | 6.24 ± 4.43 | — | 5.91 ± 3.00 | — |
| Ribociclib | — | — | — | — | — | — | — | 9.01 ± NA | 8.44 ± 2.21 | 10.7 ± NA | 7.77 ± 1.95 | 10.1 ± NA |
| Ribociclib metabolite, LEQ803 | — | — | — | — | — | — | — | 19.9 ± NA | 14.1 ± 4.04 | 19.2 ± NA | 16.0 ± 4.50 | — |
| Capmatinib | — | — | — | 2.18 ± 0.0599 | 2.50 ± NA | 2.82 ± NA | — | — | — | — | — | — |
| Buparlisib | 15.4 ± 4.62 | — | — | — | — | — | — | — | — | — | — | — |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
| Liter per hour | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encorafenib | 49.6 ± 42.1 | 44.7 ± 18.4 | 60.7 ± NA | 40.1 ± 42.6 | 18.6 ± NA | 23.4 ± 10.7 | 28.7 ± NA | 33.3 ± NA | 34.9 ± 6.9 | 32.2 ± NA | 19.5 ± 44.3 | — |
| Binimetinib | 28.5 ± 14.8 | 36.9 ± 105.7 | 35.6 ± NA | 20.8 ± 28.1 | 15.1 ± NA | 16.3 ± 5.0 | 17.4 ± NA | 15.8 ± NA | 26.5 ± 22.6 | 25.9 ± NA | 19.9 ± 29.2 | — |
| Ribociclib | — | — | — | — | — | — | — | 243 ± NA | 161 ± 61.1 | 173 ± NA | 62.4 ± 58.5 | 99.3 ± NA |
| Capmatinib | — | — | — | 65.9 ± 52.2 | 24.8 ± NA | 45.7 ± 24.4 | — | — | — | — | — | — |
| Buparlisib | 28.2 ± 53.6 | 23.2 ± NA | — | — | — | — | — | — | — | — | — | — |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution is the apparent volume of distribution at steady-state.
| Liter | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encorafenib | 268 ± 45.4 | 324 ± 69.8 | 313 ± NA | 226 ± 92.9 | 91.7 ± NA | 133 ± 13.5 | 177 ± NA | 180 ± NA | 210 ± 32.3 | 178 ± NA | 99.3 ± 46.0 | — |
| Binimetinib | 324 ± 58.3 | 185 ± 83.4 | 82.5 ± NA | 244 ± 75.9 | — | 125 ± 56.1 | 147 ± NA | 86.8 ± NA | 184 ± 111.8 | 406 ± NA | 113 ± 48.5 | — |
| Ribociclib | — | — | — | — | — | — | — | 3160 ± NA | 1930 ± 30.5 | 2660 ± NA | 677 ± 65.0 | 1440 ± NA |
| Capmatinib | — | — | — | 190 ± 30.3 | 89.5 ± NA | 233 ± NA | — | — | — | — | — | — |
| Buparlisib | 604 ± 17.4 | — | — | — | — | — | — | — | — | — | — | — |
| Nanogram per milliliter | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encorafenib | 11.3 ± 45.3 | 25.1 ± 2066.8 | 6.76 ± NA | 15.9 ± 315.9 | 5.20 ± NA | 15.0 ± 20.9 | 10.7 ± NA | 7.85 ± NA | 10.8 ± 106.1 | 10.5 ± NA | 33.7 ± 254.3 | — |
| Binimetinib | 44.1 ± 19.1 | 30.2 ± 59.2 | 55.8 ± NA | 63.2 ± 64.0 | 17.6 ± NA | 55.9 ± 54.0 | 78.3 ± NA | 29.8 ± NA | 23.1 ± 5.2 | 47.9 ± NA | 58.7 ± 60.2 | 40.5 ± NA |
| Binimetinib metabolite, AR00426032 | 3.99 ± 61.8 | 2.92 ± 159.3 | 1.82 ± NA | 5.57 ± 130.2 | 1.44 ± NA | 4.75 ± 25.4 | 6.53 ± NA | 1.08 ± NA | 2.31 ± 47.8 | 3.54 ± NA | 4.68 ± 92.3 | 1.56 ± NA |
| Ribociclib | — | — | — | — | — | — | 94.0 ± NA | 25.6 ± NA | 52.7 ± 90.4 | 34.9 ± NA | 147 ± 71.8 | 91.8 ± NA |
| Ribociclib metabolite, LEQ803 | — | — | — | — | — | — | 84.5 ± NA | 46.8 ± NA | 42.5 ± 13.8 | 22.8 ± NA | 73.2 ± 49.6 | 59.6 ± NA |
| Infigratinib | — | — | 20.5 ± NA | — | — | — | — | — | — | — | — | — |
| Infigratinib metabolite, BHS697 | — | — | 5.57 ± NA | — | — | — | — | — | — | — | — | — |
| Infigratinib metabolite, CQM157 | — | — | 32.2 ± NA | — | — | — | — | — | — | — | — | — |
| Capmatinib | — | — | — | 79.6 ± 103.1 | 58.1 ± NA | 269 ± 68.7 | — | — | — | — | — | — |
| Buparlisib | 41.8 ± 82.9 | 101 ± 1.4 | — | — | — | — | — | — | — | — | — | — |
| Nanogram per milliliter | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg | Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg | Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg | Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg | Part II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encorafenib | 11.2 ± 106.3 | 18.6 ± 159.4 | 7.74 ± NA | 11.6 ± 51.3 | 7.95 ± NA | 13.5 ± 35.0 | 9.28 ± NA | 10.3 ± NA | 7.75 ± 37.3 | 10.4 ± NA | 21.7 ± 185.4 | — |
| Binimetinib | 32.0 ± 17.1 | 39.1 ± 57.4 | 33.9 ± NA | 81.2 ± 47.5 | 47.3 ± NA | 50.9 ± 34.4 | 54.3 ± NA | 28.3 ± NA | 21.1 ± 23.7 | 31.5 ± NA | 51.0 ± 76.1 | 36.2 ± NA |
| Binimetinib metabolite, AR00426032 | 3.14 ± 74.5 | 3.80 ± 111.9 | 1.21 ± NA | 8.22 ± 84.6 | 4.36 ± NA | 5.45 ± 42.2 | 4.16 ± NA | NA ± NA | 3.81 ± NA | 1.72 ± NA | 4.34 ± 79.9 | 1.09 ± NA |
| Ribociclib | — | — | — | — | — | — | 98.4 ± NA | 28.2 ± NA | 30.7 ± 24.9 | 36.4 ± NA | 104 ± 54.2 | 64.7 ± NA |
| Ribociclib metabolite, LEQ803 | — | — | — | — | — | — | 76.0 ± NA | 37.1 ± NA | 32.9 ± 25.7 | 22.8 ± NA | 55.1 ± 33.9 | 49.2 ± NA |
| Infigratinib | — | — | 2.49 ± NA | — | — | — | — | — | — | — | — | — |
| Infigratinib metabolite, BHS697 | — | — | 1.64 ± NA | — | — | — | — | — | — | — | — | — |
| Infigratinib metabolite, CQM157 | — | — | 11.1 ± NA | — | — | — | — | — | — | — | — | — |
| Capmatinib | — | — | — | 83.9 ± 34.0 | 71.4 ± NA | 173 ± 41.2 | — | — | — | — | — | — |
| Buparlisib | 49.7 ± 115.9 | 97.3 ± 16.2 | — | — | — | — | — | — | — | — | — | — |
Collected over Day 1 up to 30 days after last dose (maximum treatment exposure for Part I was 403.7 weeks and for Part II was 97.0 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part I: Encorafenib + Binimetinib (Naive) | 20/75 (26.7%) | 47/75 (62.7%) | 75/75 (100%) |
| Part I: Encorafenib + Binimetinib (Non-naive) | 29/83 (34.9%) | 37/83 (44.6%) | 73/83 (88%) |
| Part II: Encorafenib + Binimetinib + Ribociclib | 28/38 (73.7%) | 19/38 (50%) | 33/38 (86.8%) |
| Part II: Encorafenib + Binimetinib + Infigratinib | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) |
| Part II: Encorafenib + Binimetinib + Capmatinib | 8/13 (61.5%) | 6/13 (46.2%) | 11/13 (84.6%) |
| Part II: Encorafenib + Binimetinib + Buparlisib | 4/6 (66.7%) | 4/6 (66.7%) | 5/6 (83.3%) |
| Event | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/75 | 0/83 | 1/38 | 0/1 | 0/13 | 1/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/75 | 0/83 | 1/38 | 0/1 | 0/13 | 1/6 |
| SeizureNervous system disorders | 2/75 | 0/83 | 0/38 | 0/1 | 0/13 | 1/6 |
| DeliriumPsychiatric disorders | 1/75 | 1/83 | 0/38 | 0/1 | 0/13 | 1/6 |
| Pelvic painReproductive system and breast disorders | 0/75 | 0/83 | 0/38 | 0/1 | 0/13 | 1/6 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/75 | 0/83 | 0/38 | 0/1 | 0/13 | 1/6 |
| AnaemiaBlood and lymphatic system disorders | 3/75 | 1/83 | 2/38 | 0/1 | 1/13 | 0/6 |
| Cardiac arrestCardiac disorders | 0/75 | 0/83 | 0/38 | 0/1 | 1/13 | 0/6 |
| Cardiac failureCardiac disorders | 0/75 | 0/83 | 0/38 | 0/1 | 1/13 | 0/6 |
| ColitisGastrointestinal disorders | 0/75 | 1/83 | 0/38 | 0/1 | 1/13 | 0/6 |
| Event | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib |
|---|---|---|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 38/75 | 10/83 | 5/38 | 0/1 | 2/13 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 28/75 | 16/83 | 10/38 | 0/1 | 3/13 | 3/6 |
| DiarrhoeaGastrointestinal disorders | 33/75 | 25/83 | 9/38 | 0/1 | 2/13 | 1/6 |
| FatigueGeneral disorders | 31/75 | 27/83 | 6/38 | 0/1 | 1/13 | 0/6 |
| NauseaGastrointestinal disorders | 30/75 | 33/83 | 15/38 | 0/1 | 2/13 | 2/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 26/75 | 15/83 | 2/38 | 0/1 | 0/13 | 1/6 |
| PyrexiaGeneral disorders | 13/75 | 16/83 | 7/38 | 0/1 | 0/13 | 2/6 |
| Aspartate aminotransferase increasedInvestigations | 9/75 | 6/83 | 4/38 | 0/1 | 0/13 | 2/6 |
| RetinopathyEye disorders | 22/75 | 10/83 | 0/38 | 0/1 | 0/13 | 0/6 |
| ConstipationGastrointestinal disorders | 22/75 | 13/83 | 5/38 | 0/1 | 1/13 | 1/6 |
Analysis population: participants who were treated with at least 1 dose (partial or full) of encorafenib or binimetinib in Part I and at least 1 dose of encorafenib or binimetinib or the assigned third agent following the assignment of the triple combination treatment in Part II. Parts I and II participants are not exclusive. To avoid risk of identification of participant, baseline measure data is not disclosed for reporting arm including Infigratinib and reported under category- Not Disclosed.
| Age, Customized(Participants) | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib | Total |
|---|---|---|---|---|---|---|---|
| Part I — 18-44 years | 14 | 24 | 0 | 0 | 0 | 0 | 38 |
| Part I — 45-64 years | 43 | 37 | 0 | 0 | 0 | 0 | 80 |
| Part I — 65 years and over | 18 | 22 | 0 | 0 | 0 | 0 | 40 |
| Part I — Not disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part II — 18-44 years | 0 | 0 | 9 | 0 | 0 | 1 | 10 |
| Part II — 45-64 years | 0 | 0 | 19 | 0 | 7 | 4 | 30 |
| Part II — 65 years and over | 0 | 0 | 10 | 0 | 6 | 1 | 17 |
| Part II — Not disclosed | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Sex/Gender, Customized(Participants) | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib | Total |
|---|---|---|---|---|---|---|---|
| Part I — Female | 28 | 39 | 0 | 0 | 0 | 0 | 67 |
| Part I — Male | 47 | 44 | 0 | 0 | 0 | 0 | 91 |
| Part I — Not Disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part II — Female | 0 | 0 | 22 | 0 | 5 | 1 | 28 |
| Part II — Male | 0 | 0 | 16 | 0 | 8 | 5 | 29 |
| Part II — Not Disclosed | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib | Total |
|---|---|---|---|---|---|---|---|
| Race: Part I — Caucasian | 74 | 82 | 0 | 0 | 0 | 0 | 156 |
| Race: Part I — Asian | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Race: Part I — Not Disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race: Part II — Caucasian | 0 | 0 | 37 | 0 | 13 | 6 | 56 |
| Race: Part II — Asian | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race: Part II — Not Disclosed | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Part I: Encorafenib + Binimetinib (Naive) | Part I: Encorafenib + Binimetinib (Non-naive) | Part II: Encorafenib + Binimetinib + Ribociclib | Part II: Encorafenib + Binimetinib + Infigratinib | Part II: Encorafenib + Binimetinib + Capmatinib | Part II: Encorafenib + Binimetinib + Buparlisib | Total |
|---|---|---|---|---|---|---|---|
| Ethnicity: Part I — Hispanic or Latino | 3 | 7 | 0 | 0 | 0 | 0 | 10 |
| Ethnicity: Part I — Not Hispanic or Latino | 72 | 76 | 0 | 0 | 0 | 0 | 148 |
| Ethnicity: Part I — Not Disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity: Part II — Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Ethnicity: Part II — Not Hispanic or Latino | 0 | 0 | 37 | 0 | 13 | 6 | 56 |
| Ethnicity: Part II — Not Disclosed | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2014 to primary completion in Jan 2023, 101 months.
Results were first posted in Mar 2024, 1 year 1 month after primary completion.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 101 months is above that.
Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Encorafenib · Binimetinib · Ribociclib · Infigratinib · Buparlisib · Capmatinib